New migraine pill tested in 500 patients
NCT ID NCT06414044
First seen Jan 23, 2026 · Last updated May 23, 2026 · Updated 15 times
Summary
This study looks at how well the drug atogepant works to prevent migraines in 500 adults in Italy. Participants have migraine with or without aura, or chronic migraine. The main goal is to see if the drug reduces the number of migraine days per month after three months of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fondazione Policlinico Campus Bio-Medico
Roma, 00128, Italy
-
SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi
Florence, 50134, Italy
Conditions
Explore the condition pages connected to this study.